BR9909197A - Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv - Google Patents
Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hivInfo
- Publication number
- BR9909197A BR9909197A BR9909197-6A BR9909197A BR9909197A BR 9909197 A BR9909197 A BR 9909197A BR 9909197 A BR9909197 A BR 9909197A BR 9909197 A BR9909197 A BR 9909197A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- amino
- alkyloxycarbonyl
- mono
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/48—Two nitrogen atoms
- C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/66—Derivatives of melamine in which a hetero atom is directly attached to a nitrogen atom of melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/54—Three nitrogen atoms
- C07D251/70—Other substituted melamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Patente de Invenção: <B>"DERIVADOS 1,3,5-TRIAZINA TRI-SUBSTITUìDOS PARA O TRATAMENTO DE INFECçõES POR HIV"<D>. A presente invenção refere-se ao uso dos compostos de fórmula (I) os N-óxidos, os sais de adição farmaceuticamente aceitáveis e as formas estereoquimicamente isoméricas destes, onde A é CH, CR^ 4^ ou N; n é 0, 1, 2, 3, ou 4; R¹ e e R² são cada qual, independentemente selecionados dentre hidrogênio, hidróxi, C~ 1-12~ alquila, C~ 1-12~ alquilóxi, C~ 1-12~ alquilcarbonila, C~ 1-12~ alquiloxicarbonila, arila, amino, mono- ou di(C~ 1-12~ alquil)amino, mono- ou di(C~ 1-12~alquil)aminocarbonila, onde cada um dos grupos C~ 1-12~ alquila supramencionados, podem opcionalmente, e, individualmente ser substituídos; ou R¹ ou R² considerados juntos, podem formar pirrolidinila, piperidinila, morfolinila, azido ou mono- ou di(C~ 1-12~ alquil)amino-C~ 1-4~alquilideno; R³ é hidrogênio, arila, C~ 1-6~ alquilcarbonila, C~ 1-6~ alquila, C~ 1-6~ alquiloxicarbonila, C~ 1-6~ alquila substituída com C~ 1-6~ alquiloxicarbonila; e cada R~ 4~, independentemente, é hidróxi, halo, C~ 1-6~ alquila, C~ 1-6~alquilóxi, ciano, aminocarbonila, nitro, amino, trihalometila, ou trihalometilóxi; L é -X-R^ 5^ ou -X-Alq-R^ 6^, onde R^ 5^ e R^ 6^ são cada qual, independentemente, indanila, indolila ou fenila, cada um dos grupos indanila, indolila ou fenila podendo ser substituídos; e X é -NR^ 3^-, -NH-NH-, -N=N-, -O-, -S-, -S(=O)- ou -S(=O)~ 2~); arila é fenila opcionalmente substituído; Het é um radical alifático ou aromático heterocíclico opcionalmente substituído, para a produção de um medicamento para tratamento de indivíduos sofrendo de infecção por HIV (Vírus da Imunodeficiência Humana). A invenção refere-se ainda a novos compostos que são um subgrupo dos campostos de fórmula (I), à sua preparação e às composições farmacêuticas que os compreendem.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7963398P | 1998-03-27 | 1998-03-27 | |
EP98201589A EP0945447A1 (en) | 1998-03-27 | 1998-05-14 | Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections |
PCT/EP1999/002044 WO1999050256A1 (en) | 1998-03-27 | 1999-03-24 | Trisubstituted 1,3,5-triazine derivatives for treatment of hiv infections |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9909197A true BR9909197A (pt) | 2000-12-05 |
Family
ID=22151790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9909197-6A BR9909197A (pt) | 1998-03-27 | 1999-03-24 | Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv |
Country Status (33)
Country | Link |
---|---|
US (3) | US6150360A (pt) |
EP (2) | EP0945447A1 (pt) |
JP (1) | JP2002511390A (pt) |
KR (1) | KR100593396B1 (pt) |
CN (1) | CN1157386C (pt) |
AP (1) | AP1475A (pt) |
AR (1) | AR018169A1 (pt) |
AT (1) | ATE295355T1 (pt) |
AU (1) | AU758624C (pt) |
BG (1) | BG64903B1 (pt) |
BR (1) | BR9909197A (pt) |
CA (1) | CA2324921C (pt) |
DE (1) | DE69925256T2 (pt) |
DK (1) | DK1066269T3 (pt) |
EA (1) | EA004540B1 (pt) |
EE (1) | EE200000535A (pt) |
ES (1) | ES2243056T3 (pt) |
HK (1) | HK1032394A1 (pt) |
HR (1) | HRP20000621A2 (pt) |
HU (1) | HUP0101372A3 (pt) |
ID (1) | ID26043A (pt) |
IL (1) | IL138670A (pt) |
NO (1) | NO317425B1 (pt) |
NZ (1) | NZ506787A (pt) |
OA (1) | OA11493A (pt) |
PL (1) | PL194660B1 (pt) |
PT (1) | PT1066269E (pt) |
SI (1) | SI1066269T1 (pt) |
SK (1) | SK14052000A3 (pt) |
TR (1) | TR200002761T2 (pt) |
TW (1) | TW570917B (pt) |
WO (1) | WO1999050256A1 (pt) |
ZA (1) | ZA200006042B (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19945982A1 (de) * | 1999-09-24 | 2001-03-29 | Knoll Ag | Geschwindigkeitsbestimmte Partikel |
JP4919566B2 (ja) * | 1999-09-24 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗ウイルス組成物 |
US6645964B1 (en) * | 1999-11-29 | 2003-11-11 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agent |
US6943161B2 (en) * | 1999-12-28 | 2005-09-13 | Pharmacopela Drug Discovery, Inc. | Pyrimidine and triazine kinase inhibitors |
US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
AU783981C (en) | 2000-05-08 | 2007-05-03 | Janssen Pharmaceutica N.V. | HIV replication inhibitors |
EP1282607B1 (en) | 2000-05-08 | 2015-11-11 | Janssen Pharmaceutica NV | Prodrugs of hiv replication inhibiting pyrimidines |
US6858608B2 (en) * | 2001-01-09 | 2005-02-22 | Aventis Pharma S.A. | Chemical derivatives and their application as antitelomerase agents |
US6887873B2 (en) * | 2001-03-23 | 2005-05-03 | Aventis Pharma S.A. | Triazine derivatives and their application as antitelomerase agents |
US6958211B2 (en) | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
JO3429B1 (ar) * | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
US7163943B2 (en) * | 2001-09-21 | 2007-01-16 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7169785B2 (en) * | 2001-09-21 | 2007-01-30 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
PL369600A1 (en) * | 2001-09-21 | 2005-05-02 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7112587B2 (en) | 2001-09-21 | 2006-09-26 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7132423B2 (en) * | 2001-09-21 | 2006-11-07 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
US7173032B2 (en) * | 2001-09-21 | 2007-02-06 | Reddy Us Therapeutics, Inc. | Methods and compositions of novel triazine compounds |
WO2003032903A2 (en) * | 2001-10-12 | 2003-04-24 | New York University | Trisubstituted triazines compounds with antitubulin activity |
WO2003037346A1 (en) * | 2001-10-31 | 2003-05-08 | Cell Therapeutics, Inc. | 6-phenyl-n-phenyl-(1,3,5) -triazine-2,4-diamine derivatives and related compounds with lysophphosphatidic acid acyltransferase beta (lpaat-beta) inhibitory activity for use in the treatment of cancer |
CN102151273B (zh) * | 2002-02-05 | 2015-11-25 | 安斯泰来制药有限公司 | 2,4,6-三氨基-1,3,5-三嗪衍生物 |
AR039540A1 (es) * | 2002-05-13 | 2005-02-23 | Tibotec Pharm Ltd | Compuestos microbicidas con contenido de pirimidina o triazina |
US7419984B2 (en) * | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
WO2004074266A1 (en) * | 2003-02-07 | 2004-09-02 | Janssen Pharmaceutica N.V. | Hiv inhibiting 1,2,4-triazines |
US20070232572A1 (en) * | 2003-02-07 | 2007-10-04 | Aventis Pharma S.A. | Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent |
CL2004000306A1 (es) * | 2003-02-20 | 2005-04-08 | Tibotec Pharm Ltd | Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa. |
US6875781B2 (en) * | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
US20060172010A1 (en) | 2003-07-17 | 2006-08-03 | Gael Lamoureux | Process for preparing particles containing an antiviral |
JP2006528640A (ja) * | 2003-07-22 | 2006-12-21 | ニューロジェン・コーポレーション | 置換ピリジン−2−イルアミン類縁体 |
US7335770B2 (en) * | 2004-03-24 | 2008-02-26 | Reddy U5 Therapeutics, Inc. | Triazine compounds and their analogs, compositions, and methods |
CN101035773B (zh) | 2004-08-10 | 2012-06-06 | 詹森药业有限公司 | 抑制hiv的1,2,4-三嗪-6-酮衍生物 |
TW200626560A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-carbo-or heterocyclic substituted pyrimidines |
TW200626561A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-substituted pyrimidines |
TW200626574A (en) | 2004-09-30 | 2006-08-01 | Tibotec Pharm Ltd | HIV inhibiting 5-heterocyclyl pyrimidines |
RU2403254C2 (ru) | 2004-10-29 | 2010-11-10 | Тиботек Фармасьютикалз Лтд. | Бициклические производные пиримидина, ингибирующие вич |
US7592451B2 (en) * | 2005-06-23 | 2009-09-22 | New York University | Treatment for diabetes and obesity as well as method of screening compounds useful for such treatments |
CN101245051B (zh) * | 2005-12-22 | 2011-04-20 | 中国科学院上海药物研究所 | 2,4-二取代氨基-6-取代-[1,3,5]三嗪类化合物、其制备方法、药物组合物及用途 |
EP2004632B1 (en) | 2006-03-30 | 2014-03-12 | Janssen R&D Ireland | Hiv inhibiting 5-amido substituted pyrimidines |
CN101573343B (zh) | 2006-12-29 | 2016-02-24 | 爱尔兰詹森科学公司 | 抑制人免疫缺陷病毒的6-取代的嘧啶 |
CA2923637C (en) | 2006-12-29 | 2018-10-02 | Janssen Sciences Ireland Uc | Hiv inhibiting 5,6-substituted pyrimidines |
CN103476769B (zh) | 2010-10-27 | 2016-06-01 | 沃尔特及伊莱萨霍尔医学研究院 | 抗癌剂 |
GB201119358D0 (en) | 2011-11-10 | 2011-12-21 | Lewi Paulus J | Disubstituted triazine dimers for treatment and/or prevention of infectious diseases |
GB201204756D0 (en) | 2012-03-19 | 2012-05-02 | Lewi Paulus J | Triazines with suitable spacers for treatment and/or prevention of HIV infections |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
US9914709B2 (en) * | 2013-06-21 | 2018-03-13 | Yale University | Compositions and methods of treating HIV-1 infections using same |
EP3122736A1 (en) * | 2014-03-28 | 2017-02-01 | Basf Se | Diaminotriazine derivatives as herbicides |
US10604492B2 (en) | 2015-12-24 | 2020-03-31 | The Regents Of The Universtiy Of California | CFTR regulators and methods of use thereof |
CN111629730A (zh) | 2017-08-24 | 2020-09-04 | 加利福尼亚大学董事会 | 眼部药物组合物 |
CN109053613A (zh) * | 2018-07-04 | 2018-12-21 | 复旦大学 | 含有联苯结构的二芳基三嗪类化合物及其制备方法和用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2742466A (en) * | 1956-04-17 | Chx n nhx c c | ||
US2671810A (en) * | 1952-05-24 | 1954-03-09 | Du Pont | Long-chain diketones |
BE754242A (fr) * | 1970-07-15 | 1971-02-01 | Geigy Ag J R | Diamino-s-triazines et dinitro-s-triazines |
US4096206A (en) | 1976-02-09 | 1978-06-20 | Borg-Warner Corporation | Flame-retardant triazines |
US4652645A (en) | 1983-11-16 | 1987-03-24 | Ciba-Geigy Corporation | Cationic compounds |
EP0541966A3 (en) * | 1991-11-15 | 1994-09-07 | American Cyanamid Co | Process for preparing amide derivatives from halomines and acid halides |
US5283274A (en) * | 1992-06-19 | 1994-02-01 | Uniroyal Chemical Company, Inc. | Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters |
EP0723533A1 (en) | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
GB9519197D0 (en) * | 1995-09-20 | 1995-11-22 | Affinity Chromatography Ltd | Novel affinity ligands and their use |
CN1163401A (zh) * | 1996-02-13 | 1997-10-29 | 李占元 | 全自动血球计数仪试剂及配制方法 |
CA2318362A1 (en) * | 1998-01-13 | 1999-07-22 | Sharon T. Cload | Triazine antiviral compounds |
-
1998
- 1998-05-14 EP EP98201589A patent/EP0945447A1/en not_active Withdrawn
-
1999
- 1999-03-24 EE EEP200000535A patent/EE200000535A/xx unknown
- 1999-03-24 PL PL99343195A patent/PL194660B1/pl not_active IP Right Cessation
- 1999-03-24 HU HU0101372A patent/HUP0101372A3/hu unknown
- 1999-03-24 DK DK99917863T patent/DK1066269T3/da active
- 1999-03-24 KR KR1020007007971A patent/KR100593396B1/ko not_active IP Right Cessation
- 1999-03-24 PT PT99917863T patent/PT1066269E/pt unknown
- 1999-03-24 CN CNB998044474A patent/CN1157386C/zh not_active Expired - Fee Related
- 1999-03-24 TR TR2000/02761T patent/TR200002761T2/xx unknown
- 1999-03-24 AP APAP/P/2000/001913A patent/AP1475A/en active
- 1999-03-24 EP EP99917863A patent/EP1066269B1/en not_active Expired - Lifetime
- 1999-03-24 AU AU35997/99A patent/AU758624C/en not_active Ceased
- 1999-03-24 SK SK1405-2000A patent/SK14052000A3/sk unknown
- 1999-03-24 ES ES99917863T patent/ES2243056T3/es not_active Expired - Lifetime
- 1999-03-24 JP JP2000541160A patent/JP2002511390A/ja active Pending
- 1999-03-24 NZ NZ506787A patent/NZ506787A/xx unknown
- 1999-03-24 WO PCT/EP1999/002044 patent/WO1999050256A1/en not_active Application Discontinuation
- 1999-03-24 AT AT99917863T patent/ATE295355T1/de not_active IP Right Cessation
- 1999-03-24 DE DE69925256T patent/DE69925256T2/de not_active Expired - Fee Related
- 1999-03-24 BR BR9909197-6A patent/BR9909197A/pt not_active Application Discontinuation
- 1999-03-24 CA CA002324921A patent/CA2324921C/en not_active Expired - Fee Related
- 1999-03-24 SI SI9930807T patent/SI1066269T1/xx unknown
- 1999-03-24 EA EA200000993A patent/EA004540B1/ru not_active IP Right Cessation
- 1999-03-24 ID IDW20001895A patent/ID26043A/id unknown
- 1999-03-25 US US09/276,362 patent/US6150360A/en not_active Expired - Fee Related
- 1999-03-26 AR ARP990101363A patent/AR018169A1/es unknown
- 1999-03-26 TW TW088104756A patent/TW570917B/zh not_active IP Right Cessation
-
2000
- 2000-08-08 US US09/634,340 patent/US6372729B1/en not_active Expired - Fee Related
- 2000-08-28 BG BG104716A patent/BG64903B1/bg unknown
- 2000-09-19 HR HR20000621A patent/HRP20000621A2/hr not_active Application Discontinuation
- 2000-09-25 IL IL13867000A patent/IL138670A/xx not_active IP Right Cessation
- 2000-09-26 NO NO20004809A patent/NO317425B1/no unknown
- 2000-09-27 OA OA1200000266A patent/OA11493A/en unknown
- 2000-10-26 ZA ZA200006042A patent/ZA200006042B/xx unknown
-
2001
- 2001-04-20 HK HK01102801A patent/HK1032394A1/xx not_active IP Right Cessation
-
2002
- 2002-02-05 US US10/067,383 patent/US6774235B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9909197A (pt) | Derivados 1,3,5-triazina tri-substituìdos para o tratamento de infecções por hiv | |
BR9909191A (pt) | Derivados de pirimidina inibidores do hiv | |
BR9704937A (pt) | Derivados de diamino-1,3,5-triazina substituìda | |
EA200000990A1 (ru) | Вич-ингибирующие производные пиримидина | |
BRPI0407732A (pt) | pirimidinas e triazinas inibidoras da replicação de hiv | |
BR9810097A (pt) | Derivados de macrolìdeos c-4-substituìdos | |
MX9308016A (es) | Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene. | |
AR024227A1 (es) | Pirimidinas inhibidoras de replicacion de hiv, un proceso para su preparacion, el uso de las mismas para la manufactura de un medicamento, composiciones farmaceuticas, y un proceso para prepararlas | |
ME00558A (en) | Pyrazole derivatives for treating hiv | |
BRPI9810519B8 (pt) | derivados de 4''-substituído-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. | |
BR0209267A (pt) | Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf) | |
ES2161418T3 (es) | Compuestos de piridilfurano y de piridiltiofeno y uso farmaceutico de los mismos. | |
BRPI0415759A (pt) | compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia | |
BR9912729A (pt) | Derivado de amida, processo para prepará-lo, e, uso do mesmo | |
HUP0104959A2 (hu) | 4-Kinolinkarboxamid-származékok, előállításuk, neurokinin-2 (NK-2) és neurokinin-3 (NK-3) receptor antagonistákként történő felhasználásuk, valamint a vegyületeket tartalmazó gyógyszerkészítmények | |
EA200600225A1 (ru) | Производные пиперазина для лечения вич инфекций | |
BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
BRPI0408767B8 (pt) | inlbidores da transcriptase reversa não-nucleosídeos para tratamento de doenças mediadas pelo hiv, seu uso, e composição farmacêutica | |
BR0315958A (pt) | Composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
ES2196332T3 (es) | Derivados de hexahidro-pirido(4,3-b)indol como farmacos antipsicoticos. | |
ATE500231T1 (de) | Hiv hemmende pyrimidin derivate | |
AR002264A1 (es) | 6-[triazolil[3(trifluormetil)fenil]metil]-2-quinolinonas y quinolintionas, un procedimiento para su preparacion, una composicion que las comprende, unprocedimiento para su preparacion, el uso de las mismas para la preparacion de un medicamento y un intermediario. | |
BR9915176A (pt) | Derivados de triazina dissubstituìdos nas posições 2,4 | |
BR0314709A (pt) | Derivados de pirazol | |
BR9811679A (pt) | Antifúngicos de 1,3-dioxolanos 2,4,4-trissubstituìdos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: C07D 251/70, C07D 251/52, C07D 403/12, C07D 251/42, C07D 251/50, C07D 251/66, A61K 31/53, A61P 31/18 Ipc: C07D 251/70 (2009.01), C07D 251/52 (2009.01), C07D |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |